Sugammadex in the management of myasthenic patients undergoing surgery: beyond expectations

Michele Carron, Alessandro De Cassai, Federico Linassi


Myasthenia gravis is an autoimmune disease characterized by antibodies that bind to acetylcholine receptors or functionally related molecules in the postsynaptic membrane of the neuromuscular junction. These antibodies induce skeletal muscle weakness that can be generalized or localized, is typically more severe in proximal muscles, and nearly always involves the eye, producing diplopia and ptosis.